Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

首页> 外文期刊>Nature clinical practice. Oncology >Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

【24h】

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

机译：沙利度胺维持治疗对多发性骨髓瘤患者有益吗？

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Almost all patients with multiple myeloma who receive conventional chemotherapy with autologous stem cell transplantation relapse, most within 3 years. It has been hypothesized that maintenance therapy might prolong tumor response, but the beneficial effect of maintenance therapy, with agents such as the antiangiogenic agent thalidomide, has not been proven. OBJECTIVE To evaluate the effect of thalidomide maintenance therapy on the risk of events and skeleton-related events (SREs) in patients with multiple myeloma.

机译：几乎所有多发性骨髓瘤患者均接受常规化疗并自体干细胞移植复发，大部分在3年内。已经假设维持治疗可以延长肿瘤反应，但是尚未证明维持治疗与抗血管生成剂沙利度胺等药物的有益作用。目的评估沙利度胺维持治疗对多发性骨髓瘤患者发生事件和骨骼相关事件（SRE）风险的影响。

著录项

来源
《Nature clinical practice. Oncology》 |2007年第7期|共2页
作者

展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
chromosome 13; maintenance therapy; myeloma; thalidomide;

机译：13号染色体;维持治疗;骨髓瘤;沙利度胺;

相似文献

外文文献
中文文献
专利

1. Does maintenance therapy with thalidomide benefit patients with multiple myeloma? [J] . Nature clinical practice. Oncology . 2007,第7期

机译：沙利度胺维持治疗对多发性骨髓瘤患者有益吗？
2. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP). [J] . Eom HS, Kim YK, Chung JS, Annals of hematology . 2010,第5期

机译：硼替佐米，沙利度胺，地塞米松诱导治疗，美法仑，泼尼松龙，沙利度胺巩固治疗作为非移植候选多发性骨髓瘤患者的第一线治疗方法：韩国多发性骨髓瘤工作组（KMMWP）的结果。
3. Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP) [J] . Hyeon-Seok Eom, Yeo-Kyeoung Kim, Joo-Seop Chung, Annals of Hematology . 2010,第5期

机译：硼替佐米，沙利度胺，地塞米松诱导治疗，美法仑，泼尼松龙，沙利度胺巩固治疗作为非移植候选多发性骨髓瘤患者的第一线治疗方法：韩国多发性骨髓瘤工作组（KMMWP）的结果
4. Durability of Response with Thalidomide Therapy for Relapsed Multiple Myeloma [C] . B. Myers, S.G. Jones, G. Do I an European Haematology Association . 2002

机译：耐久性耐久性与多发性骨髓瘤复发疗法
5. Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through Optimizing Osteoblastic Niche. [D] . Zhang, Wenting. 2015

机译：通过优化成骨细胞利基的原代人多发性骨髓瘤细胞的体外维持。
6. Ixazomib-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial [O] . Sonja Zweegman, Claudia A.M. Stege, Einar Haukas, 2020

机译：IXAZOMIB-羟胺胺 - 低剂量地塞米松诱导随后与新诊断的多发性骨髓瘤患者的IXAZOMIB或安慰剂进行维持治疗没有资格获得自体干细胞移植;随机阶段II Hovon-126 / NMSG的结果结果来自21.13试验
7. Maintenance therapy with bortezomib plus thalidomide or bortezomib plus prednisone in elderly multiple myeloma patients included in the GEM2005MAS65 trial [O] . Mateos, Maria Victoria, Martínez-López, Joaquín, Gutiérrez, Norma Carmen, 2016

机译：GEM2005MAS65试验纳入老年多发性骨髓瘤患者使用硼替佐米联合沙利度胺或硼替佐米联合泼尼松维持治疗

Does maintenance therapy with thalidomide benefit patients with multiple myeloma?

摘要

著录项

相似文献

相关主题

期刊订阅